XOMA Royalty (XOMA) Short-term Investments (2012 - 2026)
XOMA Royalty's (XOMA) quarterly Short-term Investments came in at $500000.0 in Q1 2026, down 64.54% year-on-year from $1.4 million in Q1 2025, and down 90.81% quarter-over-quarter from $5.4 million in Q4 2025.
XOMA Royalty (XOMA) Short-term Investments (2012 - 2026) Analysis & Trends
XOMA Royalty has disclosed Short-term Investments across 12 years of filings, most recently posting $500000.0 for Q1 2026.
- Short-term Investments for Q1 2026 came in at $500000.0, down 64.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $500000.0 (down 64.54% YoY), and the FY2025 annual result was $5.4 million, up 309.1% from the prior year.
- Short-term Investments came in at $500000.0 for Q1 2026 at XOMA Royalty, down from $5.4 million in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $45.3 million in Q3 2025 to a low of $160000.0 in Q4 2023.
- The 5-year median for Short-term Investments is $523000.0 (2022), against an average of $4.0 million.
- Across the five-year window, Short-term Investments slumped 87.04% in 2022 and jumped 5669.17% in 2025, its largest moves.
- XOMA Royalty's Short-term Investments stood at $335000.0 in 2022, then tumbled by 52.24% to $160000.0 in 2023, then soared by 731.25% to $1.3 million in 2024, then surged by 309.1% to $5.4 million in 2025, then sank by 90.81% to $500000.0 in 2026.
- The last three Short-term Investments figures came in at $500000.0 (Q1 2026), $5.4 million (Q4 2025), and $45.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 500,000.00 |
| Dec 31, 2025 | 5.44 Mn |
| Sep 30, 2025 | 45.29 Mn |
| Jun 30, 2025 | 8.80 Mn |
| Mar 31, 2025 | 1.41 Mn |
| Dec 31, 2024 | 1.33 Mn |
| Sep 30, 2024 | 785,000.00 |
| Jun 30, 2024 | 696,000.00 |
| Mar 31, 2024 | 200,000.00 |
| Dec 31, 2023 | 160,000.00 |
| Sep 30, 2023 | 214,000.00 |
| Jun 30, 2023 | 320,000.00 |
| Mar 31, 2023 | 311,000.00 |
| Dec 31, 2022 | 335,000.00 |
| Sep 30, 2022 | 443,000.00 |
| Jun 30, 2022 | 523,000.00 |
| Mar 31, 2022 | 800,000.00 |
| Dec 31, 2021 | 774,000.00 |
| Sep 30, 2021 | 3.42 Mn |
| Jun 30, 2021 | 2.31 Mn |